Clinical states in prostate cancer: Toward a dynamic model of disease progression

Urology

Volumn 55, Issue 3, 2000, Pages 323-327

  Scher, Howard I ^a,b   Heller, Glenn ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER STAGING; CASTRATION; DISEASE COURSE; HEALTH STATUS; HUMAN; MALE; METASTASIS; MODEL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STATISTICAL ANALYSIS; SURVIVAL RATE;

DISEASE PROGRESSION; HUMANS; MALE; MODELS, STATISTICAL; PROSTATIC NEOPLASMS;

EID: 0033952191     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00471-9     Document Type: Short Survey

References (21)

1. Hermanek P. TNM Atlas Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors . 1997;Springer-Verlag, Berlin.
2. Kattan M.W., Eastham J.A., Stapleton A.M.F., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 90:1998;766-771.
3. Moul J. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol. 35:1999;399-407.
4. Goto Y., Ohori M., Arakawa A., et al. Distinguishing clinically important from unimportant prostate cancers before treatment value of systematic biopsies . J Urol. 156:1996;1059-1063.
5. Colombel M., Symmans F., Gil S., et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol. 143:1993;390-399.
6. Aprikian A.G., Sarkis A.S., Fair W.R., et al. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol. 151:1994;1276-1280.
7. Scher H.I., Sarkis A., Reuter V., et al. The changing pattern of expression of the epidermal growth factor receptor and transforming growth factor-α in the progression of prostatic neoplasms. Clin Cancer Res. 1:1995;545-550.
8. Visakorpi T., Hyytinen E., Koivisto P., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 9:1995;401-406.
9. Koivisto P., Kononen J., Palmberg C., et al. Androgen receptor gene amplification a possible molecular mechanism for androgen deprivation failure in prostate cancer . Cancer Res. 57:1997;314-319.
10. Andersen P.K. Multistate models in survival analysis a study of nephropathy and mortality in diabetes . Stat Med. 7:1988;661-670.
11. Klein J.P., Keiding N., Copelan E.A. Plotting summary predictions in multistate survival models probabilities of relapse and death in remission for bone marrow transplantation patients . Stat Med. 13:1994;2315-2332.
12. Pound C.R., Partin A.W., Eisenberger M.A., et al. The natural history of progression to metastases and death from prostate cancer in men with PSA recurrence following radical prostatectomy. JAMA. 281:1999;1591-1597.
13. Stamey T.A. Making the most out of six systematic sextant biopsies. Urology. 45:1995;2-12.
14. Stamey T.A., McNeal J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA. 281:1999;1395-1400.
15. Lieber M. DNA ploidy in prostate cancer potential measurement as a surrogate endpoint biomarker . J Cell Biochem. 19:1994;246-248.
16. Brawer M.K. Quantitative microvessel density a staging and prognostic marker for human prostatic carcinoma . Cancer. 78:1996;345-349.
17. Umbas R., Isaacs W.B., Bringuier P.P., et al. Decreased-E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54:1994;3929-3933.
18. Yang R.M., Naitoh J., Murphy M., et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 159:1998;941-945.
19. Cordon-Cardo C., Koff A., Drobnjak M., et al. Distinct altered patterns of p27kip1 expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst. 90:1998;1284-1291.
20. Bookstein R., MacGrogan D., Hilsenbeck S.G., et al. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53:1993;3369-3373.
21. Slovin S.F., Scher H.I. Detectable tumor cells in the blood and bone marrow smoke or fire? Cancer. 83:1998;394-398.